KRT17 and melanoma: Studies investigating K17 at the transcriptome level (n = 24) have found K17 to hold negative prognostic value in most cancer entities (endometrial [30,71], esophageal [57], gastric [72], HNSCC [38,42,52], lung cancer [73,74], melanoma [75,76], pancreatic adenocarcinoma [50,51], and renal cell carcinoma [77]).